Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine

Publisher： Karger

E-ISSN： 1421-9824|33|2-3|164-173

ISSN： 1420-8008

Source： Dementia and Geriatric Cognitive Disorders, Vol.33, Iss.2-3, 2012-05, pp. : 164-173

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Recommendations for the Use of Donepezil 23 mg in Moderate-to-Severe Alzheimer's Disease in the Asia-Pacific Region

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 6, Iss. 3, 2016-09 ,pp. : 382-395

Karger

Access to resources Recommend Favorite

The Efficacy of Licensed-Indication Use of Donepezil and Memantine Monotherapies for Treating Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Systematic Review and Meta-Analysis

By  

Dementia and Geriatric Cognitive Disorders Extra, Vol. 1, Iss. 1, 2011-07 ,pp. : 212-227

Karger

Access to resources Recommend Favorite

Long-Term Safety and Efficacy of Donepezil in Patients with Severe Alzheimer’s Disease: Results from a 52-Week, Open-Label, Multicenter, Extension Study in Japan

By  

Dementia and Geriatric Cognitive Disorders, Vol. 27, Iss. 3, 2009-02 ,pp. : 232-239

Karger

Access to resources Recommend Favorite

Clinical Efficacy and Safety of Donepezil on Cognitive and Global Function in Patients with Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 11, Iss. 6, 2000-10 ,pp. : 299-313

Karger

Access to resources Recommend Favorite

Analysis of the Effect of Memantine in Reducing the Worsening of Clinical Symptoms in Patients with Moderate to Severe Alzheimer’s Disease

By  

Dementia and Geriatric Cognitive Disorders, Vol. 24, Iss. 2, 2007-07 ,pp. : 138-145

Karger

Access to resources Recommend Favorite